UBS Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $71
UBS analyst Joon Lee initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $71.
Share
Why It Matters
A big bank analyst says Rapport is a good company to own. When experts start watching a stock, it shows they think it has a real chance to grow.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.